Economic access to COVID testing has dominated the headlines over the last few weeks, as it should because testing is key to reducing...

This week, the FDA approved Alnylam Pharmaceuticals’ ONPATTRO™ (patisiran), an innovative RNA interference (RNAi) therapy to treat...

Skeptics of bundled payments, even if they are not proponents of line-item payments, scored a victory last week with the publication of a...

The first or second question anyone asks during a social event, or on the sidelines of a middle school soccer game, is what I do for a...

Let's discuss payers reimbursing for digital health applications

Citizens, watchdogs, and legislators again are homing in on drug developers and marketers for their high-priced products. As trade...

Maryland’s Senate Finance Committee is considering bringing the “Expensive Drugs” bill (SB 437) to the floor for deliberation and a vote....

​​ In my last (and first) blog, I talked about the concepts that CMS would like to test in Phase I of its proposed rule on Part B Drugs....

There’s no better time or way to jump into Blogworld than to postulate on a topic of great interest to the industry and one that I know a...